These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30012758)

  • 1. Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection.
    Howerton A; Seymour CO; Murugapiran SK; Liao Z; Phan JR; Estrada A; Wagner AJ; Mefferd CC; Hedlund BP; Abel-Santos E
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012758
    [No Abstract]   [Full Text] [Related]  

  • 2. A new strategy for the prevention of Clostridium difficile infection.
    Howerton A; Patra M; Abel-Santos E
    J Infect Dis; 2013 May; 207(10):1498-504. PubMed ID: 23420906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.
    Phan JR; Do DM; Truong MC; Ngo C; Phan JH; Sharma SK; Schilke A; Mefferd CC; Villarama JV; Lai D; Consul A; Hedlund BP; Firestine SM; Abel-Santos E
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0143521. PubMed ID: 34780262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fate of ingested Clostridium difficile spores in mice.
    Howerton A; Patra M; Abel-Santos E
    PLoS One; 2013; 8(8):e72620. PubMed ID: 24023628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of CamSA, a potential prophylactic compound against Clostridioides difficile infections.
    Yip C; Okada NC; Howerton A; Amei A; Abel-Santos E
    Biochem Pharmacol; 2021 Jan; 183():114314. PubMed ID: 33152344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
    Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
    J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
    Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
    J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
    Freeman J; Baines SD; Jabes D; Wilcox MH
    J Antimicrob Chemother; 2005 Oct; 56(4):717-25. PubMed ID: 16143709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection.
    Rätsep M; Kõljalg S; Sepp E; Smidt I; Truusalu K; Songisepp E; Stsepetova J; Naaber P; Mikelsaar RH; Mikelsaar M
    Anaerobe; 2017 Oct; 47():94-103. PubMed ID: 28465256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.
    Gómez S; Chaves F; Orellana MA
    Anaerobe; 2017 Dec; 48():147-151. PubMed ID: 28830842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.
    Stroke IL; Letourneau JJ; Miller TE; Xu Y; Pechik I; Savoly DR; Ma L; Sturzenbecker LJ; Sabalski J; Stein PD; Webb ML; Hilbert DW
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483125
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
    Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH
    J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.
    Vincent C; Miller MA; Edens TJ; Mehrotra S; Dewar K; Manges AR
    Microbiome; 2016 Mar; 4():12. PubMed ID: 26975510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
    Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
    J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
    Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
    Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.